survivin (baculoviral IAP repeat-containing protein 5) (21-28)
(Synonyms: H2N-Thr-Phe-Lys-Asn-Trp-Pro-Phe-Leu-OH ) 目录号 : GP10034
Cancer Biology Peptides
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Survivin (baculoviral inhibitor of apoptosis IAP repeat-containing protein-5) is a member of the IAP gene family, which has been implicated in both inhibition of apoptosis and mitosis regulation1. Survivin is one of the most uniformly up-regulated genes in tumor tissues compared with healthy tissues2. High survivin expression in the primary tumor is almost invariably associated with poor patient prognosis in many cancer types. Survivin relates to poor disease outcome in a variety of tumors, i.e., neuroblastoma3, colorectal cancer4, non-small-cell lung cancers5, B-cell lymphoma6, T-cell leukemia7, hepatocellular carcinoma, esophageal carcinoma, rectal cancer, glioma, bladder cancer, soft tissue sarcoma and astrocytic tumors.
Survivin mRNA, as measured by quantitative RT-PCR in the primary tumor, has strong and independent prognostic value in human breast cancer. Survivin mRNA concentrations in the tumor can be used to classify breast cancer patients into different risk groups. 8 Cells that are unresponsive to apoptotic triggers will also be more resistant to cytotoxic treatments, as are cells that overexpress survivin9.
References:
1.Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3:46 -54.
2.Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, et al. Analysis of human transcriptomes. Nat Genet 1999; 23:387-8.
3.Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998; 351:882-3.
4.Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998; 58:5071-4.
5.Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, et al. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999; 17:2100 -4.
6.Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96:1921-5.
7.Nakayama K, Kamihira S. Survivin an important determinant for prognosis in adult T-cell leukemia: a novel biomarker in practical hemato-oncology. Leuk Lymphoma 2002; 43:2249 -55.
8.Paul N. Span, Fred C.G.J. Sweep et al. Survivin Is an Independent Prognostic Marker for Risk Stratification of Breast Cancer Patients. Clinical Chemistry 50:11; 1986 -1993 (2004)
9.Zaffaroni N, Daidone MG. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 2002; 5:65-72.
| Cas No. | SDF | ||
| 别名 | H2N-Thr-Phe-Lys-Asn-Trp-Pro-Phe-Leu-OH | ||
| Canonical SMILES | NC(C(C)O)C(NC(CC1=CC=CC=C1)C(NC(CCCCN)C(NC(CC(N)=O)C(NC(CC2=CNC3=C2C=CC=C3)C(N4C(C(NC(CC5=CC=CC=C5)C(NC(CC(C)C)C(O)=O)=O)=O)CCC4)=O)=O)=O)=O)=O | ||
| 分子式 | C54H73N11O11 | 分子量 | 1052.22 |
| 溶解度 | ≥ 105.2mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.9504 mL | 4.7519 mL | 9.5037 mL |
| 5 mM | 0.1901 mL | 0.9504 mL | 1.9007 mL |
| 10 mM | 0.095 mL | 0.4752 mL | 0.9504 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet